Strengths and limitations of genetic mouse models of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2008.04.004PMID 18585084PMCID PMC2577895
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.

  2008cited by this paper
• Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms

  2008cited by this paper
• In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

  2008cited by this paper
• Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of α‐synuclein over‐expression

  2007cited by this paper
• Genetics of Parkinson’s disease and parkinsonism

  2007influential reference
• The parkinson's complex: Parkinsonism is just the tip of the iceberg

  2006cited by this paper
• Parkinson's disease and pesticide exposures.

  2006cited by this paper
• Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

  2006cited by this paper
• Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.

  2006cited by this paper
• Parkinson's disease models: From toxins to genes

  2005cited by this paper
• Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

  2005cited by this paper
• Genetic mouse models of parkinsonism: Strengths and limitations

  2005cited by this paper
• Toxin-induced models of Parkinson’s disease

  2005cited by this paper
• Animal models of movement disorders

  2005cited by this paper
• Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein

  2004cited by this paper
• Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

  2004cited by this paper
• Stages in the development of Parkinson’s disease-related pathology

  2004cited by this paper
• Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease

  2004cited by this paper
• Alpha-synuclein and transgenic mouse models.

  2004cited by this paper
• The rotenone model of Parkinson's disease: genes, environment and mitochondria.

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters

  2002cited by this paper
• Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  2002cited by this paper
• Basal ganglia and movement disorders: an update.

  1996cited by this paper
• Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.

  1974cited by this paper

• A novel brainstem-targeted G51D α-synuclein fibril-injected mouse model exhibits sequential emergence of sleep and motor dysfunction.

  2026cites this paper
• The role of gasotransmitters in Parkinson's disease: Interplay of nitric oxide, carbon monoxide, and hydrogen sulfide

  2025cites this paper
• Human midbrain organoids: a powerful tool for advanced Parkinson’s disease modeling and therapy exploration

  2024cites this paper
• Advances in animal models of Parkinson's disease.

  2024cites this paper
• Experimental models of Parkinson's disease: Challenges and Opportunities.

  2024cites this paper
• Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges

  2024cites this paper
• Neuroprotective Effects of Licochalcone D in Oxidative-Stress-Induced Primitive Neural Stem Cells from Parkinson’s Disease Patient-Derived iPSCs

  2023cites this paper
• Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases.

  2023cites this paper
• Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson’s Disease

  2022cites this paper
• Ketogenic therapy for Parkinson's disease: A systematic review and synthesis without meta-analysis of animal and human trials.

  2022cites this paper
• Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective

  2022cites this paper
• A Comprehensive Update of Cerebral Organoids between Applications and Challenges

  2022cites this paper
• Bioengineering of brain organoids: Advancements and challenges

  2022cites this paper
• Current and Emerging MR Methods and Outcome in Rodent Models of Parkinson’s Disease: A Review

  2021cites this paper
• Animal Models of Parkinson’s Disease

  2021cites this paper
• Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein Mutations

  2021cites this paper
• Biologia Futura: the importance of 3D organoids—a new approach for research on neurological and rare diseases

  2021cites this paper
• Alpha-Synuclein in the Blood of Mice in a Neurotoxic Model of Parkinson’s Disease

  2021cites this paper
• Quantitative Proteomic Analysis of Primitive Neural Stem Cells from LRRK2 G2019S-Associated Parkinson’s Disease Patient-Derived iPSCs

  2020cites this paper
• The Application of Brain Organoids: From Neuronal Development to Neurological Diseases

  2020cites this paper
• Stem Cell-based Therapy for Neurodegenerative Diseases

  2020cites this paper
• Back to the origins: human brain organoids to investigate neurodegeneration.

  2019cites this paper
• The Role of Lipids in Parkinson’s Disease

  2019cites this paper
• Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids

  2019cites this paper
• Sensory neuropathy and nociception in rodent models of Parkinson's disease

  2019cites this paper
• Animal Models of Parkinson’s Disease

  2018cites this paper
• Animal Models of Pathological Aging

  2018cites this paper
• The enteric nervous system in PD: gateway, bystander victim, or source of solutions

  2018cites this paper
• Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson’s disease

  2018cites this paper
• 5 Animal Models of Parkinson’s Disease

  2018influential citation
• Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms.

  2018cites this paper
• Reprint of "Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms".

  2018cites this paper
• In Vivo/In Situ Animal Models

  2017cites this paper
• Biomarker Research in Parkinson’s Disease Using Metabolite Profiling

  2017cites this paper
• RNA Interference of Human α-Synuclein in Mouse

  2017cites this paper
• Seeding and transgenic overexpression of alpha‐synuclein triggers dendritic spine pathology in the neocortex

  2017cites this paper
• Pericytes in Neurodegeneration

  2017cites this paper
• Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson’s disease

  2017cites this paper
• Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease

  2016cites this paper
• MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian

  2016cites this paper
• Stem Cell Therapy for Parkinson's Disease.

  2016cites this paper
• How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?

  2016cites this paper
• Genetic Models of Parkinson's Disease

  2015cites this paper
• Single injection of small-molecule amyloid accelerator results in cell death of nigral dopamine neurons in mice

  2015cites this paper
• Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

  2015cites this paper
• Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease

  2015cites this paper
• Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?

  2014cites this paper
• Animal models of CNS disorders.

  2014cites this paper
• Modèle progressif de la maladie de parkinson après dysfonctionnement aigu des transporteurs du glutamate dans la substance noire chez le rat.

  2013cites this paper
• Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease

  2013cites this paper
• Behavioral testing regimens in genetic-based animal models of Parkinson's disease: cogencies and caveats.

  2013cites this paper
• Cognitive deficits in animal models of basal ganglia disorders.

  2013cites this paper
• Strengths and limitations of the epidemiological approach for studying laminitis

  2013cites this paper
• An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease.

  2012cites this paper
• Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?

  2012cites this paper
• α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

  2012cites this paper
• Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.

  2012cites this paper
• Animal models of L-DOPA-induced dyskinesia: an update on the current options.

  2012cites this paper
• Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies.

  2011cites this paper
• Induced Animal Models of Parkinson’s Disease

  2011cites this paper
• New animal models of Parkinson's disease

  2011cites this paper
• Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease.

  2011cites this paper
• Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

  2011cites this paper
• Behavioral phenotyping of mouse models of neurodegeneration.

  2011cites this paper
• Parkinson’s disease mouse models in translational research

  2011influential citation
• Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein

  2011cites this paper
• Pros and cons of a prion-like pathogenesis in Parkinson's disease

  2011cites this paper
• Alterations in Corticostriatal Synaptic Function in Huntington's and Parkinson's Diseases

  2010cites this paper
• Evaluation of an Infertile Transgenic Male Animal

  2010cites this paper
• Staging of α‐synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved

  2010cites this paper
• Inflammation in transgenic mouse models of neurodegenerative disorders.

  2010cites this paper
• Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

  2010cites this paper
• Non-mammalian animal models of Parkinson's disease for drug discovery

  2010cites this paper
• Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice

  2010cites this paper
• Genetic animal models of Parkinson's disease.

  2010influential citation
• Proteomics in Parkinson’s disease: current trends, translational snags and future possibilities

  2010cites this paper
• Parkin interacts with the 26S proteasome via Rpn13, a novel ubiquitin receptor

  2010cites this paper
• The Immunological Impact of Genetic Drift in the B10.BR Congenic Inbred Mouse Strain1

  2009cites this paper
• The importance of molecular histology to study glial influence on neurodegenerative disorders. Focus on recent developed single cell laser microdissection

  2009cites this paper
• Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease

  2009cites this paper
• Strain in the B10.BR Congenic Inbred Mouse The Immunological Impact of Genetic Drift

  2009cites this paper